A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)
Phase of Trial: Phase II
Latest Information Update: 28 May 2018
At a glance
- Drugs Ifetroban (Primary)
- Indications Aspirin-induced asthma
- Focus Therapeutic Use
- Sponsors Cumberland Pharmaceuticals
- 18 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 18 May 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
- 06 Mar 2018 According to a Cumberland Pharmaceuticals media release, this follow-on Boxaban (Ifetroban) study received FDA clearance earlier in the year (2017).